The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)

Clancy, Michael; Hall, Samuel

Previous article The EU Commission accepts commitments made by a pharmaceutical company to reduce prices for six off-patent cancer medicines by 73% addressing excessive pricing concerns (Aspen) Next article The Chinese State Administration for Market Regulation publishes anti-monopoly guidelines on platform economy

10 Feb 2021

The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen)

KEYWORDS

Reference

EU Commission, Aspen, Press release, 10 February 2021

In February 2021, the European Commission’s (“Commission”) long-running excessive pricing case against Aspen was brought to a close, with Aspen accepting a series of forward-looking pricing and supply commitments, but avoiding any fines or requirements to repay all of the higher prices charged (see VBB on Competition Law, Volume 2021, No. 2). This appears to have been a good result for Aspen, particularly in comparison with the € 5.2 million fine received in the 2016 decision from the Italian competition authority. Against this backdrop, it is

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Michael Clancy
Van Bael & Bellis (Brussels)

France 38 contributions 20741 visits
Samuel Hall
Van Bael & Bellis (Brussels)

Belgium 19 contributions 7444 visits

Quotation

Michael Clancy, Samuel Hall, The EU Commission accepts the commitment offered by a pharmaceutical company for excessive pricing (Aspen), 10 February 2021, e-Competitions February 2021, Art. N° 100835

Visites 261